Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model The Ii-Key vaccine elicits both CD4+ T Helper cell (Th1) and CD8+ responses that are ...
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
Generex Biotechnology Corporation (OTC:GNBT) announced today the signing of a Letter of Intent to acquire 51 percent of Olaregen Therapeutix Inc., a New York-based regenerative medicine company.
$50 million licensing deal for the Ii-Key platform to develop vaccines for infectious diseases and cancer Deal includes first contract for Ii-Key- SARS-CoV-2 vaccine against COVID-19 in China with a ...
MIRAMAR, Fla., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) is pleased to announce that Generex has acquired an additional 38% of ...
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into ...
MIRAMAR, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on August 18, 2020. The corrected press release reads: Generex Biotechnology Corporation ...
WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer ...
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding WORCESTER, Mass. and TORONTO, April 23, 2015 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) ...
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced an ...
Positive interim results from Phase 2b breast cancer study of AE37 presented last month at a major scientific breast cancer conference enable update to clinical development & regulatory strategy and ...
Generex, a biotech company based in Miramar, issued a shareholder alert Wednesday warning that allegedly illicit activity has adversely affected its share price. The company said it believes ...
TORONTO -- Generex Biotechnology Corporation announced today that its wholly owned subsidiary, Antigen Express, has established collaborations with Emory University and the Imperial College of London ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results